LexBlog IP

DECEMBER 21, 2023

STELARA® (ustekinumab) Four months after Janssen Biotech, Inc. 10,961,307 (“the ’307 Patent”), directed to methods of treating ulcerative colitis with ustekinumab, Biocon Biologics Inc. Both patents are assigned to Regeneron Pharmaceuticals, Inc., Samsung has now advanced further than Apotex Inc.

Patent 52

Patent Reporting Settlement Intellectual Property 52

Canadian Intellectual Property Blog

JUNE 21, 2022

Canada’s Patented Medicine Prices Review Board (PMPRB) is a quasi-judicial body that has authority under the Patent Act to protect and inform Canadians “by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends”. [1] 1] [link] [2] Alexion Pharmaceuticals v.

Patent 52

Patent Intellectual Property Intellectual Property Law Reporting 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

As of the March 23, 2020 transition, however, all “biological product” applications previously approved under the FD&C Act were “deemed” approved under the PHS Act, and companies can now seek biosimilars and interchangeables of these biological products. As noted above, companies are already taking advantage of these new designations.

Settlement 52

Settlement Litigation Marketing Marketing 52